# Assurex Health

> Pharmacogenomic testing (GeneSight) to guide mental health medication decisions — acquired by Myriad Genetics.

## Why it is interesting

Cincinnati-metro (Mason, OH) precision-medicine exit: Myriad deal $225M upfront (+$185M milestones) in 2016; early CincyTech support; HQ kept in Mason.

## Profile

- **Stage:** acquired
- **Status:** acquired
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-26

## Key facts

- Acquired by Myriad Genetics (2016): $225M upfront + up to $185M milestones
- HQ remained Mason, Ohio post-deal
- Early investor/support: CincyTech
- Product: GeneSight psychotropic genetic testing

## Investors in our directory

- https://venturecapitaltracker.com/fund/cincytech

---
Source: https://venturecapitaltracker.com/startup/assurex-health